HighTide Therapeutics Inc (2511.HK)

4.880 +0.060 (+1.24%) At close: 04:08PM HKT

HighTide Therapeutics Inc

18B-102, Zhonghaixin Innovation Industry City
Ganli Second Road Jihua Neighborhood Longgang District
Shenzhen 518112
China
86 755 2662 6253
https://www.hightidetx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Liping Liu	CEO & Chairwoman	3.93M	N/A	1970
Ms. Meng Yu	Deputy GM & Executive Director	1.48M	N/A	1982
Mr. Koon Yin Sim	Chief Financial Officer	N/A	N/A	1970
Dr. Leigh Anne MacConell	Chief Development Officer	N/A	N/A	1967
Ms. Yu Li	VP & Joint Company Secretary	N/A	N/A	1977
Ms. Pik Man Chu	Joint Company Secretary	N/A	N/A	1997

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of therapies for the treatment of metabolic and digestive diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis; in phase III clinical trial to treat type 2 diabetes mellitus; is in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangitis, as well as in phase II clinical trial to treat primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTD1804 that is in preclinical trial to treat obesity; HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases; and HTD2802 that is in preclinical trial for treating inflammatory bowel disease. The company was founded in 2011 and is headquartered in Shenzhen, China.

Corporate governance

HighTide Therapeutics Inc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.